61Cu-based AlphaFlare radiodiagnostic - NUCLIDIUM
Alternative Names: 61Cu-based AlphaFlare™ radiodiagnostic - NUCLIDIUMLatest Information Update: 04 Apr 2023
At a glance
- Originator NUCLIDIUM
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Head and neck cancer; Pancreatic cancer
Most Recent Events
- 29 Mar 2023 61Cu-based AlphaFlare radiodiagnostic - NUCLIDIUM is available for licensing as of 29 Mar 2023. https://nuclidium.com/about-us/
- 29 Mar 2023 Early research in Pancreatic cancer (Diagnosis) in Switzerland (unspecified route) before March 2023 (NUCLIDIUM pipeline, March 2023)
- 28 Mar 2023 Early research in Head and neck cancer (Diagnosis) in Switzerland (unspecified route) before March 2023 (NUCLIDIUM pipeline, March 2023)